Literature DB >> 7797787

Reproducibility of allergen-induced early and late asthmatic responses.

M D Inman1, R Watson, D W Cockcroft, B J Wong, F E Hargreave, P M O'Byrne.   

Abstract

BACKGROUND: Constant-dose allergen inhalation challenges are frequently used to examine the effect of antiasthma drugs on the allergen-induced early and late asthmatic responses. The end-point measurements in such studies are the maximal early and late percent decreases in the forced expiratory volume in 1 second (FEV1).
OBJECTIVE: Our purpose was to observe the reproducibility and to determine the sample sizes required for such studies.
METHODS: Twenty-eight subjects with allergen-induced early and late responses were studied with two constant-dose allergen challenges separated by 2 to 12 weeks. The early response was measured as the maximum percent decrease in FEV1 during the first 2 hours and the late response as the maximum percent decrease in FEV1 between 3 to 7 hours.
RESULTS: The mean +/- SEM early responses were 23.1% +/- 1.0% and 24.7% +/- 2.0%, whereas the mean late responses were 23.3% +/- 2.0% and 24.5% +/- 2.2%. Reproducibility of measurements were such that fewer than eight subjects are required, to show 50% attenuation of either the early or late response (with 90% power).
CONCLUSIONS: The method of constant-dose allergen challenge is a sensitive tool for detecting changes in early and late asthmatic responses after the use of antiasthma medication.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7797787     DOI: 10.1016/s0091-6749(95)70075-7

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  9 in total

Review 1.  Measurement of airway hyperresponsiveness: new considerations.

Authors:  J Lötvall; M Inman; P O'Byrne
Journal:  Thorax       Date:  1998-05       Impact factor: 9.139

2.  The reproducibility of bolus allergen challenges; power calculations for clinical trials.

Authors:  Raminder Aul; Hayley King; Umme Kolsum; Dave Singh
Journal:  Eur J Clin Pharmacol       Date:  2012-11-06       Impact factor: 2.953

Review 3.  Investigative bronchoprovocation and bronchoscopy in airway diseases.

Authors:  William W Busse; Adam Wanner; Kenneth Adams; Herbert Y Reynolds; Mario Castro; Badrul Chowdhury; Monica Kraft; Robert J Levine; Stephen P Peters; Eugene J Sullivan
Journal:  Am J Respir Crit Care Med       Date:  2005-07-14       Impact factor: 21.405

4.  Contrasting effects of allergen challenge on airway responsiveness to cysteinyl leukotriene D(4) and methacholine in mild asthma.

Authors:  R I Ketchell; M D'Amato; M W Jensen; B J O'Connor
Journal:  Thorax       Date:  2002-07       Impact factor: 9.139

5.  Comparing the effects of two inhaled glucocorticoids on allergen-induced bronchoconstriction and markers of systemic effects, a randomised cross-over double-blind study.

Authors:  Jan Lötvall; Mona Palmqvist; Peter Arvidsson
Journal:  Clin Transl Allergy       Date:  2011-10-31       Impact factor: 5.871

Review 6.  Precision Medicine in House Dust Mite-Driven Allergic Asthma.

Authors:  Ibon Eguiluz-Gracia; Francisca Palomares; Maria Salas; Almudena Testera-Montes; Adriana Ariza; Ignacio Davila; Joan Bartra; Cristobalina Mayorga; Maria Jose Torres; Carmen Rondon
Journal:  J Clin Med       Date:  2020-11-26       Impact factor: 4.241

Review 7.  Allergen provocation tests in respiratory research: building on 50 years of experience.

Authors:  Gail M Gauvreau; Beth E Davis; Guy Scadding; Louis-Philippe Boulet; Leif Bjermer; Adam Chaker; Donald W Cockcroft; Barbro Dahlén; Wyste Fokkens; Peter Hellings; Nikolaos Lazarinis; Paul M O'Byrne; Ellen Tufvesson; Santiago Quirce; Maurits Van Maaren; Frans H de Jongh; Zuzana Diamant
Journal:  Eur Respir J       Date:  2022-08-25       Impact factor: 33.795

Review 8.  Profile of lebrikizumab and its potential in the treatment of asthma.

Authors:  Diego Jose Maselli; Holly Keyt; Linda Rogers
Journal:  J Asthma Allergy       Date:  2015-08-10

9.  Modulation of allergen-induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination.

Authors:  A Oliver; L Bjermer; D Quinn; P Saggu; P Thomas; K Yarnall; J Lötvall
Journal:  Allergy       Date:  2013-08-07       Impact factor: 13.146

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.